Avoro Capital Advisors AKRO Position
Exited13-Fund ConvergenceAvoro Capital Advisors exited their position in Akero Therapeutics Inc. (AKRO) in Q4 2023, after holding the stock for 2 quarters.
The position was first reported in Q3 2023 and has been tracked across 2 quarterly 13F filings.
AKRO is a convergence signal: 13 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Efruxifermin in 14 days (Apr 30, 2026), making the timing of Avoro Capital's position particularly relevant.
About Akero Therapeutics Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Full company profile →Avoro Capital Advisors AKRO Position History
Frequently Asked Questions
Does Avoro Capital Advisors own AKRO?
No. Avoro Capital Advisors exited their position in Akero Therapeutics Inc. (AKRO) in Q4 2023. They previously held the stock for 2 quarters.
How many hedge funds own AKRO?
13 specialist biotech hedge funds currently hold AKRO, including RTW Investments, Deep Track Capital, Baker Bros. Advisors and 10 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy AKRO?
Avoro Capital Advisors's position in AKRO was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's AKRO position increasing or decreasing?
Avoro Capital Advisors completely exited their AKRO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AKROCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →